Literature DB >> 22702470

Increased human tumor necrosis factor-α levels induce procoagulant change in porcine endothelial cells in vitro.

Kyoung Geun Lee1, Haneulnari Lee, Jeong Mi Ha, Young Kyung Lee, Hee Jung Kang, Chung-Gyu Park, Sang Joon Kim.   

Abstract

BACKGROUND: Intravascular thrombosis and systemic coagulation abnormalities are major hurdles to successful xenotransplantation and are signs of acute humoral rejection. Increased expression of tissue factor (TF) is associated with the development of microvascular thrombosis in xenografts. To develop an effective strategy to prevent accelerated coagulation in xenografts, we investigated the mechanism by which porcine endothelial cells (PECs) become procoagulant after contact with human blood.
METHODS: The changes in TF mRNA levels and activity in PECs after incubation with 20% human serum or human bioactive molecules, including C5a, tumor necrosis factor-α (TNFα) and interleukin (IL)-1α, were evaluated using real-time PCR and the factor Xa chromogenic assay, respectively. The procoagulant changes in PECs by these agonists were evaluated by measuring the coagulation time of human citrated plasma suspended with PECs pretreated with each agonist. TF expression and coagulation times were also assessed in PECs transfected with short interfering RNA (siRNA) designed to knock down porcine TF. We also examined the production of proinflammatory cytokines in human whole-blood or plasma after contact with PECs, which were screened using the cytometric bead array system. TNFα levels were measured using ELISA in whole-blood after contact with PECs, with or without the addition of xenoreactive antibodies or C1 esterase inhibitor.
RESULTS: Porcine TF mRNA and activity in PECs were up-regulated in response to human TNFα and IL-1α but were not affected by C5a or 20% human serum. Up-regulation of TF expression by human TNFα or IL-1α shortened PEC-induced coagulation time, while siRNA-mediated knockdown of TF expression prolonged coagulation time. The incubation of PECs with human whole-blood led to a significant increase in human TNFα levels in the blood, which was promoted by the addition of xenoreactive antibodies and prevented by C1 esterase inhibitor.
CONCLUSIONS: Human TNFα level increases in human blood after contact with PECs, which is attributed to xenoreactive antibody binding and subsequent complement activation. Human TNFα induces procoagulant changes in PECs with increased TF expression. This study suggests that human TNFα may be one of the mediators linking complement activation with procoagulant changes in the xenoendothelium.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22702470     DOI: 10.1111/j.1399-3089.2012.00704.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  4 in total

Review 1.  The production of multi-transgenic pigs: update and perspectives for xenotransplantation.

Authors:  Heiner Niemann; Bjoern Petersen
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

2.  Aged-Related Changes in Body Composition and Association between Body Composition with Bone Mass Density by Body Mass Index in Chinese Han Men over 50-year-old.

Authors:  Ying Jiang; Ying Zhang; Mengmeng Jin; Zhaoyan Gu; Yu Pei; Ping Meng
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

3.  Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue.

Authors:  Elizaveta Fasler-Kan; Natasha S Barteneva; Sylvia Ketterer; Kerstin Wunderlich; Anca Reschner; Asil Nurzhanova; Josef Flammer; Jörg Huwyler; Peter Meyer
Journal:  Xenotransplantation       Date:  2013-11-01       Impact factor: 3.907

4.  The Role of Interleukin-6 (IL-6) in the Systemic Inflammatory Response in Xenograft Recipients and in Pig Kidney Xenograft Failure.

Authors:  Guoqiang Zhang; Hayato Iwase; Qi Li; Takayuki Yamamoto; Abhijit Jagdale; Mohamed B Ezzelarab; David Ayares; David K C Cooper; Hidetaka Hara; Gangcheng Wang
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.